Joinn Laboratories China Co Ltd
SSE:603127
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (6.5), the stock would be worth ¥16.17 (60% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16 | ¥39.95 |
0%
|
| 3-Year Average | 6.5 | ¥16.17 |
-60%
|
| 5-Year Average | 10.3 | ¥25.82 |
-35%
|
| Industry Average | 6.1 | ¥15.35 |
-62%
|
| Country Average | 3.3 | ¥8.24 |
-79%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
¥24.3B
|
/ |
Jan 2026
¥1.7B
|
= |
|
|
¥24.3B
|
/ |
Dec 2026
¥1.9B
|
= |
|
|
¥24.3B
|
/ |
Dec 2027
¥2.2B
|
= |
|
|
¥24.3B
|
/ |
Dec 2028
¥3B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
J
|
Joinn Laboratories China Co Ltd
SSE:603127
|
29.9B CNY | 16 | 100.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 328.4 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 4.6 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 5.6 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 17.9 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
329.9B CNY | 6.5 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | 5.5 | -118.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 4.7 | 24.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 9.2 | 44.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 2.4 | 19.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 6.8 | 29 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 3.3 |
| 70th Percentile | 6.2 |
| Max | 5 034 353.9 |
Other Multiples
Joinn Laboratories China Co Ltd
Glance View
Nestled in the bustling heart of China's vibrant biomedical sector, Joinn Laboratories China Co Ltd has emerged as a pivotal player in advancing the field of pharmaceutical research and development. Founded with a vision to revolutionize the landscape of drug testing and safety evaluation, Joinn Laboratories operates as a comprehensive preclinical contract research organization (CRO). The company specializes in providing a wide array of services including toxicology, pharmacology, and bioanalytical testing that are crucial in the early stages of drug development. With an expansive network of state-of-the-art laboratories and a team of highly skilled scientists, Joinn facilitates the essential task of ensuring that pharmaceutical products meet rigorous safety and efficacy standards before advancing to clinical trials. Joinn Laboratories generates revenue primarily by offering these indispensable services to pharmaceutical companies and biotech firms worldwide. By acting as an external testing partner, Joinn allows its clients to significantly streamline their drug development processes, reducing both time and cost associated with bringing a new drug to market. Their business model thrives on the growing demand for outsourced R&D capabilities, a trend fueled by the increasing complexity and regulatory requirements in drug approval processes. The company leverages its expertise and cutting-edge technology to deliver precise and reliable data, thus providing a seamless bridge between scientific discovery and market-ready pharmaceutical solutions.